Pedro Segura-Saldaña

Pedro Segura-Saldaña

Auto-generated profile, based on publicly available information

Pedro Segura-Saldaña

Departamento de Ingeniería Biomédica, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Cardiovascular Pathology
Verified
Journal Article
Closed access
CACristian Aguilar
Cristian Aguilar
BBBrady Beltran
Brady Beltran
PQPilar Quiñones
Pilar Quiñones
TCTomas Carbajal
Tomas Carbajal
JVJorge Vilcapaza
Jorge Vilcapaza
JCJorge J Castillo
Jorge J Castillo

4 September 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
KMKatia Menacho
Katia Menacho
SRSara Ramirez
Sara Ramirez
PSPedro Segura
Pedro Segura
SNSabrina Nordin
Sabrina Nordin
AAAmna Abdel‐Gadir
Amna Abdel‐Gadir
JMJames C. Moon
James C. Moon
Background: Advanced cardiac imaging permits optimal targeting of cardiac treatment but needs to be faster, cheaper, and easier for global delivery. We aimed to pilot rapid cardiac magnetic resonance ( CMR ) with contrast in a developing nation, embedding it within clinical care along with training and mentoring. Methods and Results: A cross‐sectional study of CMR delivery and clinical impact assessment performed 2016–2017 in an upper middle‐income country. An International partnership (clinicians in Peru and collaborators from the United Kingdom, United States, Brazil, and Colombia) developed and tested a 15‐minute CMR protocol in the United Kingdom, for cardiac volumes, function and scar, and delivered it with reporting combined with training, education and mentoring in 2 centers in the capital city, Lima, Peru, 100 patients referred by local doctors from 6 centers. Management changes related to the CMR were reviewed at 12 months. One‐hundred scans were conducted in 98 patients with no complications. Final diagnoses were cardiomyopathy (hypertrophic, 26%; dilated, 22%; ischemic, 15%) and 12 other pathologies including tumors, congenital heart disease, iron overload, amyloidosis, genetic syndromes, vasculitis, thrombi, and valve disease. Scan cost was $150 USD, and the average scan duration was 18±7 minutes. Findings impacted management in 56% of patients, including previously unsuspected diagnoses in 19% and therapeutic management changes in 37%. Conclusions: Advanced cardiac diagnostics, here CMR with contrast, is possible using existing infrastructure in the developing world in 18 minutes for $150, resulting in important changes in patient care.

9 August 2020 in Neuropathology
Verified
Journal Article
Open access
PDF file
CACristian Aguilar
Cristian Aguilar
TCTomas Carbajal
Tomas Carbajal
BBBrady E. Beltran
Brady E. Beltran
PSPedro Segura
Pedro Segura
SMSajjad Muhammad
Sajjad Muhammad
JCJoham Choque-Velasquez
Joham Choque-Velasquez
Systemic embolization has been reported in up to 40% of patients with left atrial myxoma, half of them with cerebral involvement. However, development of intracerebral embolization associated with parenchymal seeding of the myxoma emboli is an extremely rare complication, with only 36 histologically diagnosed cases reported in the published literature. We describe a 69‐year‐old woman who arrived at the emergency service with hemiparesis associated with drug‐resistant epilepsy and a medical history of resection of a left atrial myxoma 10 months previously. Cranial computed tomography revealed multiple large lesions of heterogeneous density and cystic components in the occipital lobes and posterior fossa parenchyma. Histopathological analyses after stereotactic biopsy of the occipital lesion revealed infiltrative myxoma cells with benign histological findings and uniform expression of calretinin similar to that of the primary cardiac myxoma. Additional immunohistochemical studies confirmed brain parenchymal seeding of the myxoma cells with strong expression of interleukin‐6 (IL‐6) and focal expression of matrix metalloproteinases‐2 (MMP‐2). Here, we discuss the clinicopathological features of intracerebral embolization of left atrial myxomas associated with progressive parenchymal seeding of the tumor emboli and the potential pathogenic role of IL‐6 and MMPs.

23 July 2020 in Journal of Arrhythmia
Verified
Journal Article
Open access
PDF file
AGAna C. Gonzales‐Luna
Ana C. Gonzales‐Luna
JTJavier O. Torres‐Valencia
Javier O. Torres‐Valencia
JAJavier E. Alarcón‐Santos
Javier E. Alarcón‐Santos
PSPedro A. Segura‐Saldaña
Pedro A. Segura‐Saldaña
Objectives The purpose of this article was to determine the change in the volume of pacemaker implantations with the COVID‐2019 pandemic and to assess the change in the number of pacemaker implants according to etiology during the pandemic. Background The establishment of a mandatory social isolation have generated a decrease in activities in cardiology units. Methods Descriptive, cross‐sectional study that used a database of a Peruvian Hospital. Time was divided into three categories: Before COVID period and COVID period including Previous to Social isolation (SI) and Social Isolation. The number of pacemaker implantations were compared per the same amount of time. Results A reduction in the pacemaker implant of 73% (95% CI: 33‐113; P < .001) was observed during the COVID‐19 pandemic period, and a reduction of 78% of patients with the diagnosis of complete or high‐grade atrioventricular block and a reduction in the de‐novo pacemaker implant was observed, regardless of the etiology. Conclusions Our results indicate a very significant reduction (73%) in de‐novo pacemaker implantation during the months of the COVID‐19 pandemic. The reduction in the number of de‐novo pacemaker occurred independent of the etiology.

31 May 2021 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MGMartín Gómez-Luján
Martín Gómez-Luján
CCCesar Cruzalegui
Cesar Cruzalegui
CACristian Aguilar
Cristian Aguilar
MAMayita Alvarez-Vargas
Mayita Alvarez-Vargas
PSPedro Segura-Saldaña
Pedro Segura-Saldaña
Fabry disease (FD), like COVID-19, can affect multiple organs, including the lungs. Patients with FD would be expected to develop severe forms of COVID-19, not only because of lung involvement but also because of renal involvement and other comorbidities. We present two cases of patients with Fabry disease who had an infection by COVID-19. In the two cases presented, they presented mild forms of COVID-19. Although the role of the X chromosome mutation in FD on the development of severe forms of COVID-19 is unknown; in the cases presented, it is suggested that it may play a protective role in the development of COVID-19. Two cases are presented; it is suggested that FD would not be a risk factor for severe COVID-19.

12 May 2023 in High Blood Pressure & Cardiovascular Prevention
Verified
Journal Article
Open access
PDF file
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
FRFernando M. Runzer-Colmenares
Fernando M. Runzer-Colmenares
PSPedro A. Segura-Saldaña
Pedro A. Segura-Saldaña
Introduction COVID-19 related mortality is about 2%, and it increases with comorbidities, like hypertension. Regarding management, there is debatable evidence about the benefits of continuation vs. discontinuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB). Aim We performed a systematic review to assess the effects and safety of in-hospital discontinuation compared to continuation of ACEI/ARB in COVID-19 patients. Methods We systematically searched on PubMed, Scopus, and EMBASE from inception to June 19, 2021. We included observational studies and trials that compared the effects and safety of continuing ACEI/ARB compared to discontinuing it in COVID-19 patients. Effects sizes for dichotomous variables were expressed as risk ratios (RR) and 95% confidence intervals. For continuous variables, effects were expressed as mean difference (MD). We used random effect models with the inverse variance method. We assessed certainty of evidence using the GRADE approach. Results We included three open-label randomized controlled trials and five cohort studies. We found that the continuation group had lower risk of death compared with the discontinuation group only in the cohort group (RR: 0.46, 95% CI: 0.24–0.90), but not in the RCT group (RR: 1.22, 95% CI: 0.75–2.00). The ICU admission rate was significantly lower in the continuation group (RR: 0.46, 95% CI: 0.31–0.68) in the cohort group, but not in RCT group (RR: 1.03, 95% CI: 0.67–1.59). We did not find significant differences between groups regarding hospitalization length, hypotension, AKI needing renal replacement therapy, mechanical ventilation, new or worsening heart failure, myocarditis, renal replacement therapy, arrhythmias, thromboembolic events and SOFA AUC. The GRADE approach revealed that the certainty ranged from moderate to high level. Conclusions There is no significant difference in mortality and other outcomes between continuation and discontinuation groups.